CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 261 enrolled
Drug / intervention
Fluticasone furoate +1 moredrug
Likely dose
Fluticasone furoate 55 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01630135
NCT01630135Phase 3Completed
CompareCT.gov

Study FFR116364, a Double-blind, Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

GlaxoSmithKline·interventional·Posted Jun 28, 2012·Updated Jan 11, 2017

In Brief

A Phase 3 clinical trial evaluating Fluticasone furoate and Placebo for Rhinitis, Allergic, Perennial. Completed, enrolled 261 participants across 22 sites.

Detailed Summary

Efficacy and safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 2 weeks in Japanese paediatric subjects ages 6 to \< 15 years with perennial allergic rhinitis will be evaluated compared with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Perennial
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 28, 2012
Enrollment StartJun 1, 2012
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.0 years ago

Interventions

Fluticasone furoatedrug

55 mcg/day, intranasal, 2 weeks

Placebodrug

Placebo, intranasal, 2 weeks